Related Experiment Video
Updated: Dec 21, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Learning from Cochrane systematic reviews: what improvements do these suggest for the design of trials?
Stefania Pirosca1, Mike Clarke2, Shaun Treweek3
1School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK.
Abstract:
Background: Many randomised trials have serious methodological flaws that fatally undermine their results, which makes the research wasteful. This is of concern for many, including those doing systematic reviews that include trials. Cochrane systematic reviews have a section called ' Implications for research', which allows authors of the review to present their conclusions on how future research might be improved. Looking at these conclusions might highlight priority areas for improvement. Methods: We focused on the Cochrane Schizophrenia Review Group and the Multiple sclerosis and rare diseases of the central nervous system Review Group (the MS Review Group). Reviews with citation dates between 2009 and 2019 were identified and the recommendations of review authors in ' Implications for research' were put into categories. Results: Between 2009 and 2019 we identified 162 reviews for the Schizophrenia Review Group and 43 reviews for the MS Review Group. We created 22 categories of recommendations in total, of which 12 were common to both groups. The five most used categories were the same for both: better choice of outcomes; better choice of intervention/comparator; longer follow-up; larger sample size; use of validated scales. Better choice of outcomes and/or intervention/comparator was recommended in over 50% of reviews. Longer follow-up and larger sample size were recommended in over a third, with use of validated scales being suggested in around a fifth of reviews. There was no obvious pattern of improvement over time for trials included in systematic reviews published by both groups. Conclusions: We suggest that trialists working in these and other areas ask themselves, or are compelled to do so by others (e.g. funders), why they have chosen their outcomes, intervention and comparator, whether follow-up is long enough, if the sample size is big enough and whether the scales they choose to measure their outcomes are appropriate.
More Related Videos
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
06:05The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
Published on: February 19, 2021
Related Concept Videos
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Study Designs in Epidemiology
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
Study Design in Statistics
Does aspirin reduce the risk of heart attacks? Is one brand of fertilizer more effective at growing roses than another? Is fatigue as dangerous to a driver as the influence of alcohol? Questions like these are answered using randomized experiments with proper...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Dosage Regimens: Designs and Approaches
Crossover Experiments
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.